Mr Olgierd Świerzewski > Kochanski & Partners > Warsaw, Poland > Lawyer Profile
Kochanski & Partners Offices
PL PILSUDSKIEGO 1
- Go to...
Mr Olgierd Świerzewski
Technology Transactions & Financial Services; Pharmaceuticals Health Care & Life Sciences
Partner, Executive Director, Head of Technology Transactions Practice, Financial Services and Pharmaceuticals Health Care & Life Sciences
Technology Transactions & Financial Services
Olgierd is a partner and Chair in the Technology Transactions group and has been recognised as a Recommended Lawyer in the “Banking and Finance” sector by the Legal500. He was also nominated as In-house Legal of the Year in 2018 by prestigious magazine The Lawyer, and is also a Project Management Professional certified by the most prestigious global project management organization, the Project Management Institute.
Olgierd has extensive experience in regulatory risk management and conducting analyses and assessments of the impact of regulatory changes on company operations. He has coordinated numerous projects related to anticipating legal risk and assessment of the impact of new legislation on business, i.a. for the Government of the Republic of Poland, the Organization for Economic Cooperation and Development and also within pharmaceutical and IT companies and banks from the private sector.
His practice focuses primarily on technology transactions and transfers, fundraising and financing, joint ventures, technology procurement, outsourcing, and advising on data protection, and the regulatory aspects of digital business.
Olgierd also spent 8 years as General Counsel for Accor Hotels with responsibility for 16 countries in Europe, and in addition has worked in-house on secondment to IT giant Dell.
Olgierd has significant experience in advising in M&A transactions (to, among others: Starbucks Coffee, BP Poland, Teich, Aviko, Royal Cosun, Caparo Engineering, PKP Cargo, UGI Corporation, Varian Medical Technologies, Bravura Solutions, IFS, Hanseatic Capital, AccorHotels), as well as in the area of Facility Agreements and Regulatory Finance (i.a. the Royal Bank of Scotland, Barclays, Kaupthing Bank, UBS International, WestLB, GE Bank, the Bank of China).
Pharmaceuticals Health Care & Life Sciences
Olgierd has extensive experience in regulatory risk management and in analysing and assessing the impact of regulatory changes on company operations.
He has coordinated numerous projects related to anticipating legal risk and assessment of the impact of new legislation on business, i.a. for government authorities of the Republic of Poland, the Organization for Economic Cooperation and Development, and pharmaceutical companies.
Olgierd has advised, among others, on the legal aspects of drug reimbursement, clinical trials, authorisation of medicinal products, advertising and promotional activities, distribution, international expansion, protection of industrial property rights, interpretation of Community regulations and directives in the context of Polish legislation. He has also advised on cooperation and joint venture agreements and transactions, and project management.
During his professional career Olgierd has advised both Polish and foreign clients from the pharmaceutical sector, including:
- GlaxoSmithKline, Novartis,
- Sanofi Synthelabo, Polpharma S.A.,
- KRKA Polska Sp. z o.o., BIOTON S.A.
- Wyeth Pharmaceuticals Ltd.,
- Superpharm Poland Sp. z o.o.,
- Grifols Polska Sp. z o.o.,
- Dr August Wolff Bielefeld GmbH,
- International Nephrology Centers Poland Sp. z o.o.,
- Biotechnology Company Ltd.,
- Ferring, Blaufarma Sp. z o.o.,
- Polfa Pabianice S.A.,
- Medicover Sp. z o.o.,
- Ergomed Sp. z o.o.,
- Heraeus Medical GmbH,
- Pharmaco International Holdings Ltd.,
- Varian Medical Technologies Ltd.,
- Medimedia International Ltd.,
- Farma Biagini S.P.A.,
- Kutnowskie Zakłady Farmaceutyczne „Polfa” S.A. (currently Teva).
His legal advice has covered issues such as:
- clinical trials of medicinal products and medical devices,
- drug registration and post-registration changes,
- cooperation with pharmacies,
- advertising of medicines and dietary supplements,
- Regulatory Compliance,
- proceedings before the Main Pharmaceutical Inspector (GIF), the Office for Registration of Medicinal Products, Medical Devices and Biocidal Products (URPL), the Ministry of Health, and pharmaceutical law matters,
- industry codes of good practice,
- medical incidents,
- reimbursement of medicinal products, medical devices and foodstuffs for particular nutritional uses.
Polish, English, Russian.
The Warsaw Bar Association, Project Management Institute.
The Warsaw University (Master of Law, 1995), The Warsaw School of Economics (Postgraduate studies on Management & Marketing). Project Management Professional certified by PMI.
The TMT group at Kochanski & Partners is led by Olgierd Świerzewski and Piotr Kochanski. A key name for cybersecurity matters, the team recently established the Anti-Fraud Association to focus on the identification and prevention of economic crime. The team has also handled a substantive amount of cloud computing implementation for financial services sector clients. Karolina Marciniszyn is another key name to note.
Under the leadership of Olgierd Świerzewski, the team at Kochanski & Partners advises pharmaceutical and life sciences companies on all aspects of their production and distribution in Poland. The group assists with regulatory issues, with recent experience in issues surrounding medical marijuana and CBD. During the Covid-19 pandemic, the team was instructed by the Mazovian Provincial Office on a pro bono basis to advise on agreements for the purchase of critical medical supplies. Other key lawyers include pharmaceutical law and distribution expert Krzysztof Zieba and Karolina Jasiulewicz, a company and commercial law specialist with experience advising healthcare companies.
Kochanski & Partners‘ financial services team handles a variety of transactions (including real estate, acquisition and asset financings), refinancing issues and financial restructuring. The group is also regularly instructed by banks on regulatory issues, with an increasing focus on fintech. In 2020, the banking regulatory practice was boosted by the arrival of counsel Artur Bilski from Alior Bank, adding expertise in European regulations, anti-money laundering issues and consumer protection law. The group is led by financial transactional lawyer Olgierd Świerzewski, who advises foreign investors on their business in Poland, as well as domestic banks and financial institutions.
The team at Kochanski & Partners handles private equity transactions for funds and target companies, with demonstrable expertise in the real estate sector. The group is split between the corporate and real estate departments, under the leadership of Rafał Rapala and Paweł Cholewiński. With Olgierd Świerzewski, the team has a specialist in regulator risk and deals in the technology industry.
- Banking and finance - Poland
- Healthcare and life sciences - Poland
- Private equity - Poland
- TMT - Poland